MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 202514 | Name: Rostaporfin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Rostaporfin (also known as REM-001, tin ethyl etiopurpurin, Sn(IV) etiopurpurin, Purlytin, SnET2), is a synthetic purpurin with photosensitizing activity. Rostaporfin preferentially accumulates in tumor cells due to an increased rate of metabolism. Upon exposure to a light source, this agent absorbs light, forming an extended high energy conformational state that produces high quantum yields of singlet oxygen with local cytotoxic effects.

Chemical Structure

Rostaporfin
Rostaporfin
CAS#284041-10-7

Theoretical Analysis

MedKoo Cat#: 202514

Name: Rostaporfin

CAS#: 284041-10-7

Chemical Formula: C37H42Cl2N4O2Sn

Exact Mass: 764.1707

Molecular Weight: 764.37

Elemental Analysis: C, 58.14; H, 5.54; Cl, 9.28; N, 7.33; O, 4.19; Sn, 15.53

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
SnET2; Sn(IV) etiopurpurin; Purlytin; tin ethyl etiopurpurin dichloride; tin etiopurpurin dichloride; Trademarks: Photrex; Purlytin; REM-001; REM 001; REM001;
IUPAC/Chemical Name
(OC-6-13)-Dichloro(rel-ethyl(18R,19S)-3,4,20,21-tetradehydro-4,9,14,19-tetraethyl-18,19-dihydro-3,8,13,18-tetramethyl-20-phorbinecarboxylato(2-)-kappaN(sup 23), kappaN(sup 24), kappaN(sup 25), kappaN(sup 26))tin
InChi Key
MSEVUQJXHVRVMJ-HQTZEDFWSA-M
InChi Code
InChI=1S/C37H43N4O2.2ClH.Sn/c1-10-23-19(6)29-17-33-25(12-3)21(8)34(40-33)26-15-27(36(42)43-14-5)37(13-4)22(9)30(41-35(26)37)18-32-24(11-2)20(7)28(39-32)16-31(23)38-29;;;/h15-18,22H,10-14H2,1-9H3,(H-,38,39,40,41,42);2*1H;/q-1;;;+2/p-1/t22-,37-;;;/m1.../s1
SMILES Code
CCC1=C(C2=CC3=C(C(=C4[N-]3[Sn+4]56(N2=C1C=C7[N-]5C8=C(C=C([C@]8([C@@H]7C)CC)C(=O)OCC)C9=N6C(=C4)C(=C9C)CC)([Cl-])[Cl-])C)CC)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>5 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 764.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Sivaprasad S, Hykin P. The role of photodynamic therapy in ophthalmology. Br J Hosp Med (Lond). 2006 Dec;67(12):647-50. Review. PubMed PMID: 17328448. 2: Chakravarthy U, Soubrane G, Bandello F, Chong V, Creuzot-Garcher C, Dimitrakos SA 2nd, Korobelnik JF, Larsen M, Monés J, Pauleikhoff D, Pournaras CJ, Staurenghi G, Virgili G, Wolf S. Evolving European guidance on the medical management of neovascular age related macular degeneration. Br J Ophthalmol. 2006 Sep;90(9):1188-96. PubMed PMID: 16929063; PubMed Central PMCID: PMC1857411. 3: Jankun J, Keck RW, Skrzypczak-Jankun E, Lilge L, Selman SH. Diverse optical characteristic of the prostate and light delivery system: implications for computer modelling of prostatic photodynamic therapy. BJU Int. 2005 Jun;95(9):1237-44. PubMed PMID: 15892808. 4: Skrzypczak-Jankun E, Borbulevych OY, Melillo A, Keck R, Soriano-Garcia M, Aniola J, Niedre M, Lilge L, Selman SH, Jankun J. Aspirin blocks binding of photosensitizer SnET2 into human serum albumin: implications for photodynamic therapy. Int J Mol Med. 2005 May;15(5):777-83. PubMed PMID: 15806298. 5: Zimcík P, Miletín M. [Photodynamic therapy as a new prospective method for cancer treatment--II. Overview of photosensitizers]. Ceska Slov Farm. 2004 Nov;53(6):271-9. Review. Czech. PubMed PMID: 15630992. 6: Poriel C, Kessel D, Vicente MG. Stability of tin etiopurpurin. Photochem Photobiol. 2005 Jan-Feb;81(1):149-53. PubMed PMID: 15560741. 7: Lilge L, Pomerleau-Dalcourt N, Douplik A, Selman SH, Keck RW, Szkudlarek M, Pestka M, Jankun J. Transperineal in vivo fluence-rate dosimetry in the canine prostate during SnET2-mediated PDT. Phys Med Biol. 2004 Jul 21;49(14):3209-25. PubMed PMID: 15357193. 8: Jankun J, Lilge L, Douplik A, Keck RW, Pestka M, Szkudlarek M, Stevens PJ, Lee RJ, Selman SH. Optical characteristics of the canine prostate at 665 nm sensitized with tin etiopurpurin dichloride: need for real-time monitoring of photodynamic therapy. J Urol. 2004 Aug;172(2):739-43. PubMed PMID: 15247773. 9: Gloi AM, Beck E. Threshold dose of three photosensitizers in dogs with spontaneous tumors. Vet Ther. 2003 Fall;4(3):269-78. PubMed PMID: 15136988. 10: Rostaporfin: PhotoPoint SnET2, Purlytin, Sn(IV) etiopurpurin, SnET2, tin ethyl etiopurpurin. Drugs R D. 2004;5(1):58-61. Review. PubMed PMID: 14725496. 11: Garbo GM, Vicente MG, Fingar V, Kessel D. Effects of ursodeoxycholic acid on photodynamic therapy in a murine tumor model. Photochem Photobiol. 2003 Oct;78(4):407-10. PubMed PMID: 14626670. 12: Gloi AM, Beck E. Biodistribution of three photosensitizers in dogs with spontaneous tumors. Vet Ther. 2003 Summer;4(2):155-65. PubMed PMID: 14506591. 13: Hunt DW. Rostaporfin (Miravant Medical Technologies). IDrugs. 2002 Feb;5(2):180-6. PubMed PMID: 12861479. 14: Zennaro D, Wellig P, Koch VM, Moschytz GS, Läubli T. A software package for the decomposition of long-term multichannel EMG signals using wavelet coefficients. IEEE Trans Biomed Eng. 2003 Jan;50(1):58-69. PubMed PMID: 12617525. 15: Ning MY, Li TF, Li QS. [Study of the interactions between diorganotin (IV) complexes of 1,3-dimethyl-4-acetyl-5-pyrazolone and mononucleotides and DNA]. Yao Xue Xue Bao. 2002 Jun;37(6):433-6. Chinese. PubMed PMID: 12579799. 16: Aniola J, Selman SH, Lilge L, Keck R, Jankun J. Spatial distribution of liposome encapsulated tin etiopurpurin dichloride (SnET2) in the canine prostate: implications for computer simulation of photodynamic therapy. Int J Mol Med. 2003 Mar;11(3):287-91. PubMed PMID: 12579328. 17: Lim JI. Photodynamic therapy for choroidal neovascular disease: photosensitizers and clinical trials. Ophthalmol Clin North Am. 2002 Dec;15(4):473-8, vii. Review. PubMed PMID: 12515080. 18: Woodburn KW, Engelman CJ, Blumenkranz MS. Photodynamic therapy for choroidal neovascularization: a review. Retina. 2002 Aug;22(4):391-405; quiz 527-8. Review. PubMed PMID: 12172104. 19: Renno RZ, Miller JW. Photosensitizer delivery for photodynamic therapy of choroidal neovascularization. Adv Drug Deliv Rev. 2001 Oct 31;52(1):63-78. Review. PubMed PMID: 11672876. 20: Shuler MF, Borrillo JL, Ho AC. Photodynamic therapy update. Curr Opin Ophthalmol. 2001 Jun;12(3):202-6. Review. PubMed PMID: 11389347.

View History

HR011303

HR011303